14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AAPG vs GSRFU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Ascentage Pharma Group International American Depository Shares (AAPG) is the stronger overall head-to-head candidate over GSR IV Acquisition Corp. Units (GSRFU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAPG carries a Unified Composite Score of 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin), whereas GSRFU carries 54.7/100 (HOLD) at $10.45 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While GSRFU currently prints a higher short-term Unified Composite Score (54.7/100 HOLD vs. AAPG 37.1/100 SELL), AAPG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-219.5% vs. N/A operating margin) and revenue trajectory (+29.3% vs. N/A YoY).
Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8); meanwhile GSRFU trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPG vs GSRFU. Trailing 12-month operating profitability (AAPG -219.5% vs GSRFU N/A) and valuation multiples (AAPG 8.4x vs GSRFU N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AAPG vs GSRFU Key Questions & Quantitative Answers
As of Nov 20, 2026, Ascentage Pharma Group International American Depository Shares (AAPG) is the stronger overall head-to-head candidate over GSR IV Acquisition Corp. Units (GSRFU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAPG carries a Unified Composite Score of 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin), whereas GSRFU carries 54.7/100 (HOLD) at $10.45 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While GSRFU currently prints a higher short-term Unified Composite Score (54.7/100 HOLD vs. AAPG 37.1/100 SELL), AAPG captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-219.5% vs. N/A operating margin) and revenue trajectory (+29.3% vs. N/A YoY). Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8); meanwhile GSRFU trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AAPG leads the Growth & Scale pillar: AAPG posts +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin), compared with GSRFU at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AAPG generates $643M in USD-normalized revenue versus N/A for GSRFU. In operating R&D and SG&A reinvestment, AAPG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GSRFU.
AAPG screens cheaper on headline valuation multiples. AAPG trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported EBITDA margin), whereas GSRFU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAPG (-236.6% ROE) versus GSRFU (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 64% Vol realized risk). By comparison, GSRFU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.01β · 10% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.